Lupin Ltd Q4 FY2023 Concall Summary

Key Takeaways

• India and US margins drive the quarter: India business returned to 11.3% growth (IQVIA) and US margins improved for a third straight quarter, even as gross margins stayed flat and input-cost inflation persisted.
• Tiotropium is the near-term catalyst: The drug master file cleared, pD-pK cleared, and management says a CRL would be "highly surprising"; approval and launch are targeted for H1 FY24.
• A ₹550 cr cost-savings program is delivering, but inflation is eating the gains: Over ₹325–350 cr has been achieved across three of four levers, yet a large portion was wiped out by secular input-cost inflation above 5%.
• The diabetes drag in India is structural, not terminal: Diabetes de-grew because of in-licensed product genericization and DPP-4/SGLT2 patent cliffs, but the ex-diabetes portfolio grew 15%+ and management expects double-digit India growth overall.
• What to watch next quarter: Whether Tiotropium launches on time, the pace of the promised sequential margin improvement from Q2 onward, and whether the India sales-force expansion converts into sustained double-digit growth.

US Business: The Tiotropium Bet and Base Stability

• Tiotropium is the needle-mover: The DMF cleared last week, pD-pK cleared earlier, and only minor queries remain. Management views a CRL as "highly surprising" and hopes for approval before the August TAD date, with launch ready immediately.
• Spiriva launch timing: Expected June or July, based on FDA approval. Even without Spiriva, management says the base is set at current levels, but Spiriva is the largest margin needle-mover.
• Other launches stacking up: Darunavir in June, Cyanocobalamin from Somerset in August, Diazepam Gel in July, Varenicline (TAD October), and Bromfenac (Prolensa) at the tail end of March, contingent on Pithampur Unit-2 clearance.
• Albuterol share holding: Management expects pricing to remain stable and hopes to sustain 20%+ share; no near-term entrant is expected in the next 12 months, and the company is ready to take share if market disruptions occur.
• Suprep exclusivity window: No imminent approval is believed based on supply-chain understanding; the next three to six months should remain exclusive, possibly beyond.
• Price erosion normalizing: Price erosion has settled at a mid-to-high single-digit run rate, and customers are prioritizing reliability of supply over price, shifting dialogue from transactional to partnering.
• US revenue flatness explained: Q4 revenue was \$175 mn, flat QoQ despite one extra month of Xopenex and Brovana and an AG launch in mid-December. Q3 seasonality (flu products, albuterol) caused a slight albuterol volume dip in Q4, offset by strong Suprep performance.

Vinita Gupta: "That would be highly surprising. I mean it's hard to predict the agency at any point in time, but just based on where we are, we feel like we are close to the finish line here."

India Business: Diabetes Headwind Masks a Growth Story

• India returned to double-digit growth: IQVIA growth of 11.3% in Q4 followed quarters of 1%, 6.2%, and 7.5%. Ex-diabetes, the portfolio grew 15%+, in line with the market.
• Diabetes is a top-line story, not a margin story: The de-growth comes from in-licensed products facing competition and price reductions, plus DPP-4s and SGLT2s going off patent. Because the in-licensed portfolio carries a lower margin profile than own-manufactured products, the bottom-line impact is muted.
• Diabetes growth capped for two years: Management expects diabetes to remain at high-single-digit growth, not reaching double-digit, through 2025. Everything else in India is expected to grow at double-digit rates.
• Sales-force expansion underway: Five new divisions were added in Q4 (roughly 1,000 new representatives), with a sixth extra-urban division launching in Q1. The annualization impact of Q4 recruitment will be captured across the full current fiscal year.
• India pricing dynamics: On scheduled products, WPI-linked increases are taken; on the non-scheduled portion, a 5%–6% price increase is typical. Significant input-cost inflation from anti-infectives, vitamins, and China-sourced materials cannot be directly passed on in India, with only one opportunity per year to address pricing.
• NLEM impact: The additional NLEM list had a negative impact on the controlled-product portfolio from November/December.

Nilesh Gupta: "I couldn't help but smile when you were saying the question. I think there's a massive opportunity in India... I don't think it's competition with each other... I don't think it's going to have a reflection on pricing."

Margins: Cost Savings vs. Inflation

• EBITDA improved 170 bps QoQ: Driven by optimization endeavors, lowered other expenses, and PLI benefits. Gross margins were nearly flat at 59.7% vs 59.8% QoQ, with India sales mix playing a part in the slight dip.
• Cost-savings program delivered, but inflation erased much of it: Over ₹325–350 cr was achieved across at least three of four levers, but secular input-cost inflation above 5% wiped out a large portion of those gains on the gross margin line.
• Additional ₹250 cr runway: Further potential savings exist across inventory write-offs, facilities, R&D, and oral solid dosages, achievable over 18–24 months. Inventory write-offs and idle-time improvements are not a switch-on/switch-off exercise and will take several quarters.
• Failure-to-supply penalty dropped sharply: The penalty came down from roughly \$26–27 mn last year to high single-digit millions. Management declined to make the number explicit.
• Remediation spend elevated: Compliance spend is roughly \$20 mn annually, driven by nitrosamine work and observations at Tarapur, Mandideep, and Pithampur. This is expected to normalize in the second half of the fiscal.
• Employee cost outlook: QoQ increase was driven by India field-force expansion, higher bonus accruals, and US ESOPs. Management expects employee cost to settle around 19% on an ongoing basis.
• EBITDA margin guidance: Exit run rate of 18%+ by end of FY24; full year upward of 15%. Q2–Q4 should see sequential improvements after Spiriva, Darunavir, and other US launches, plus Fostair expansion in Europe.

Ramesh Swaminathan: "We have been able to achieve well over 325 to 350 crores across at least three of the four levers that we have progressed along. There is of course some more steam left as far as the inventory write off's concerned and we believe on the idle time as well which is not a switch on, switch off kind of a thing."

Pipeline & Portfolio: Complex Generals Pivot

• R&D pivoting to complex generics: Oral solids salience is coming down from well above 45% to much lower figures. Inhalation and injectable spends are going up this fiscal and going forward. NCE spend is now very small, under 5%, after ramping down discovery infrastructure and saving ₹70–80 cr.
• R&D spend magnitude: Expected around ₹1,300–1,400 cr max.
• Injectable pipeline building: Liraglutide, Glucagon, and Caplin products were filed in FY23. Six or so injectable products are coming to market in FY24; larger products like Glucagon and Risperdal Consta are expected in FY25, which is seen as a big ramp-up year.
• Nasal sprays and respiratory: Three nasal sprays were filed in the year, adding to the respiratory portfolio. Ellipta and Respimat filings are expected in FY25.
• ForDoz partnership: Doxycycline has been filed with a TAD date soon, intended to launch in the next 12 months. Ambisome remains in development. The partnership is limited to these two products.
• Caplin Point products: Approval received for some products; five or six are intended to launch in the next 12 months.
• Pegfilgrastim: All queries have been responded to; approval is expected if the FDA has no objection.

Regional & API Performance

Compliance & Remediation

• Positive outcomes achieved: Ankleshwar, Vizag, Nagpur injectables, and Somerset sites saw positive outcomes. Substantial progress was made on remediation at Tarapur, Mandideep Unit 1, and Pithampur Unit 2.
• Remediation timeline: A large part of remediation is expected to complete in the first half of FY24, with optimization thereafter and some flowing into the second half. Management is close to remediation of Tarapur and Mandideep; for Pithampur, the goal is to close out all observations with the next update and then engage the FDA for feedback.
• Remediation spend quantified: Per an analyst's math, remediation spend is roughly \$20 mn annually, though management noted a portion was already in the base and not all of it is incremental.

Guidance & Commitments

Key Metrics